Aaron Kantoff
Director/Board Member chez AVALO THERAPEUTICS, INC.
Fortune : 28 M $ au 31/01/2024
Profil
Aaron Kantoff was the founder of Rayzebio, Inc. (founded in 2020) and Petrichor Scion Therapeutics Management LLC (founded in 2022) where he holds the titles of Director and General Partner respectively.
He currently holds the position of Executive Director-Business Development at Braeburn Pharmaceuticals SPRL and is also a Director at Marengo Therapeutics, Inc., Silagene, Inc., Ceptur Therapeutics, Inc., Tourmaline Sub, Inc., Tourmaline Bio, Inc., and Avalo Therapeutics, Inc. In his former positions, Mr. Kantoff was a Director at Syntimmune, Inc. (2014-2018), Cure Forward Corp., Corvidia Therapeutics, Inc. (2016-2019), Marengo Therapeutics, Inc., Limelight Bio, Inc., Akero Therapeutics, Inc. (2018-2019), Centessa Pharmaceuticals Plc (2021-2022), and Medicxi Ventures (Jersey) Ltd.
(2020-2021).
He also worked as an Analyst at Rothschild, Inc. in 2009 and as a Vice President at Apple Tree Venture Management LLC (2013-2019).
Mr. Kantoff obtained his undergraduate degree from The Leonard N Stern School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RAYZEBIO, INC.
0,72% | 15/09/2023 | 441 547 ( 0,72% ) | 27 M $ | 31/01/2024 |
0,18% | 24/10/2023 | 45 391 ( 0,18% ) | 1 M $ | 31/03/2024 |
Postes actifs de Aaron Kantoff
| Sociétés | Poste | Début |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director/Board Member | 28/03/2024 |
Marengo Therapeutics, Inc.
 Marengo Therapeutics, Inc. BiotechnologyHealth Technology Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA. | Director/Board Member | - |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Director/Board Member | 01/04/2022 |
| Petrichor Scion Therapeutics Management LLC | Founder | 01/01/2022 |
Ceptur Therapeutics, Inc.
 Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Director/Board Member | - |
Silagene, Inc.
 Silagene, Inc. Medical/Nursing ServicesHealth Services Silagene, Inc. provides health care services. The company is headquartered in Hillsborough, NJ. | Director/Board Member | - |
Braeburn Pharmaceuticals SPRL
 Braeburn Pharmaceuticals SPRL Medical SpecialtiesHealth Technology Braeburn Pharmaceuticals SPRL develops and commercializes medical products. It’s a pharmaceutical company focused on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. The firm offers Probuohine, CAM2038q1w, CAM2038q4w and Risperdone implant. The company was founded in 2012 and is headquartered in Road Town, British Virgin Islands. | Corporate Officer/Principal | - |
Anciens postes connus de Aaron Kantoff
| Sociétés | Poste | Fin |
|---|---|---|
| RAYZEBIO, INC. | Founder | 26/02/2024 |
| CENTESSA PHARMACEUTICALS PLC | Director/Board Member | 01/07/2022 |
| ░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Aaron Kantoff
| The Leonard N Stern School of Business | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AVALO THERAPEUTICS, INC. | Health Technology |
| AKERO THERAPEUTICS, INC. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| CENTESSA PHARMACEUTICALS PLC | Health Technology |
| Entreprise privées | 13 |
|---|---|
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
Cure Forward Corp.
 Cure Forward Corp. Miscellaneous Commercial ServicesCommercial Services Cure Forward Corp. provides lab testing services. The firm's services create a platform to connect patients with genomic medicine and bring the possibilities of precision medicine directly in reach. The company was founded by Martin Naley in 2014 and is headquartered in Cambridge, MA. | Commercial Services |
Rothschild, Inc.
 Rothschild, Inc. Investment ManagersFinance Part of Rothschild & Co. The private company is based in New York, NY. Continuation Holdings AG, Rothschild, Inc. provides investment banking and advisory services. | Finance |
Apple Tree venture Managemnet Llc//vc
 Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Finance |
Braeburn Pharmaceuticals SPRL
Braeburn Pharmaceuticals SPRL Medical SpecialtiesHealth Technology Braeburn Pharmaceuticals SPRL develops and commercializes medical products. It’s a pharmaceutical company focused on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. The firm offers Probuohine, CAM2038q1w, CAM2038q4w and Risperdone implant. The company was founded in 2012 and is headquartered in Road Town, British Virgin Islands. | Health Technology |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Finance |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Marengo Therapeutics, Inc.
Marengo Therapeutics, Inc. BiotechnologyHealth Technology Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA. | Health Technology |
Limelight Bio, Inc.
 Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Silagene, Inc.
Silagene, Inc. Medical/Nursing ServicesHealth Services Silagene, Inc. provides health care services. The company is headquartered in Hillsborough, NJ. | Health Services |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Health Technology |
| Petrichor Scion Therapeutics Management LLC | Finance |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
